Comparison of the reintroduced MEIA assay with HPLC-MS/MS for the determination of whole-blood sirolimus from transplant recipients

Therapeutic Drug Monitoring
Raymond G MorrisAnastasia Theodossi

Abstract

Therapeutic monitoring with dosage individualization of sirolimus drug therapy is standard clinical practice for organ transplant recipients. For several years sirolimus monitoring has been restricted as a result of lack of an immunoassay. The recent reintroduction of the microparticle enzyme immunoassay (MEIA) for sirolimus on the IMx analyser has the potential to address this situation. This study, using patient samples, has compared the MEIA sirolimus method with an established HPLC-tandem mass spectrometry method (HPLC-MS/MS). An established HPLC-UV assay was used for independent cross-validation. For quality control materials (5, 11, 22 microg/L), the MEIA showed acceptable validation criteria based on intra- and inter-run precision (CV) and accuracy (bias) of <8% and <13%, respectively. The lower limit of quantitation was found to be approximately 3 microg/L. The performance of the immunoassay was compared with HPLC-MS/MS using EDTA whole-blood samples obtained from various types of organ transplant recipients (n = 116). The resultant Deming regression line was: MEIA =1.3 x HPLC-MS/MS + 1.3 (r = 0.967, S(y/x) = 1) with a mean bias of 49.2% +/- 23.1% (range, -2.4% to 128%; P<0.001). The reason for the large and variable bi...Continue Reading

References

Dec 5, 1998·Journal of Chromatography. B, Biomedical Sciences and Applications·P J Taylor, A G Johnson
Apr 19, 2000·Clinical Transplantation·B D KahanC T Van Buren
May 24, 2000·Clinical Therapeutics·H U Meier-Kriesche, B Kaplan
May 24, 2000·Clinical Therapeutics·A MacDonaldJ J Zimmerman
Nov 25, 2000·Journal of Chromatography. B, Biomedical Sciences and Applications·U ChristiansG I Kirchner
Apr 17, 2001·Pharmaceutical Research·V P ShahA Yacobi
Aug 29, 2001·Clinical Pharmacokinetics·K Mahalati, B D Kahan
Oct 17, 2001·Transplantation·B D Kahan, J S Camardo
Jul 27, 2002·Therapeutic Drug Monitoring·Takafumi KuzuyaToshitaka Nabeshima
May 27, 2003·Therapeutic Drug Monitoring·Paul J Taylor, Raymond G Morris
Sep 24, 2004·Therapeutic Drug Monitoring·Mary F PainePaul B Watkins
Apr 6, 2005·Transplantation Proceedings·D W HoltA Johnston
May 21, 2005·Therapeutic Drug Monitoring·Ian S WestleyMaree J James

❮ Previous
Next ❯

Citations

Feb 13, 2007·Analytical and Bioanalytical Chemistry·Jun ZhangLewis Schwartz
Apr 13, 2007·Clinical Biochemistry·David A ColantonioWilliam Clarke
May 17, 2008·Pediatric Transplantation·Guido FillerUwe Christians
Nov 16, 2010·Biomedical Chromatography : BMC·R Nageswara RaoSachin B Agwane
Jan 31, 2014·Clinical Transplantation·David W HoltGary L Horowitz
Sep 16, 2008·Transplantation Proceedings·M J WuC H Chen
Jan 3, 2007·Journal of Mass Spectrometry : JMS
May 1, 2019·Combinatorial Chemistry & High Throughput Screening·Ataman Gönel, Ismail Koyuncu
Nov 22, 2011·Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences·Pierre-Olivier HétuBernard Vinet
Mar 26, 2020·Anti-inflammatory & Anti-allergy Agents in Medicinal Chemistry·Ataman Gönel, Idris Kirhan

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.